On Friday (22), the National Health Surveillance Agency (Anvisa) approved the update of two vaccines against Covid-19 in Brazil. They are Spikevax, developed by Adium, and Comirnaty, created by Pfizer.
With the new authorized compositions, both immunizers will be able to change the strain used in manufacturing. Anvisa’s most recent recommendation, published on April 26, establishes the need to adapt vaccines against the JN 1 variant. coronavirus – considered of interest and currently dominant in the world, despite being low risk.
This update is also in accordance with the technical note from the World Health Organization (WHO), which suggests periodic modification of doses, as is already the case with immunizations against Influenza.
Click here to read more
1732491509
#Anvisa #approves #update #vaccines #Covid19 #Brazil
What are the benefits of adapting Covid-19 vaccines to emerging variants like JN 1, according to public health experts?
**Interview with Dr. Maria Santos, Vaccinology Expert**
**Interviewer:** Thank you for joining us today, Dr. Santos. Recently, Anvisa approved updates to the Covid-19 vaccines Spikevax and Comirnaty to address the new JN 1 variant. What are the implications of this decision for public health in Brazil?
**Dr. Maria Santos:** Thank you for having me. The approval by Anvisa is a significant step in ensuring that our vaccination strategies remain effective against emerging variants. By adapting these vaccines to the JN 1 strain, we are aligning with the recommendations from the World Health Organization regarding the periodic updating of vaccines. This is crucial as we strive to maintain herd immunity and reduce transmission rates within the community.
**Interviewer:** Some might question the urgency of updating these vaccines, considering the JN 1 variant is described as low risk. What would you say to those concerns?
**Dr. Maria Santos:** It’s understandable to have questions about the necessity of these updates, especially with a variant that is labeled low risk. However, the virus is dynamic, and even low-risk variants can impact transmission rates or give rise to more dangerous strains if left unchecked. Proactively updating vaccines helps us stay ahead of potential surges and ensures a stronger public health response.
**Interviewer:** What do you think about the public perception of these updates? Some might fear they are unnecessary, or even a way for pharmaceutical companies to profit further. How should we address these fears?
**Dr. Maria Santos:** Transparency is key. It’s important to communicate the scientific rationale behind these updates and the benefits of staying ahead of the virus. Engaging with the public through information campaigns can help mitigate fears. We must emphasize that these adaptations are based on sound scientific evidence and are necessary for protecting public health—not just a business strategy.
**Interviewer:** Thank you, Dr. Santos. to engage our audience, what are your thoughts on how the public should respond to vaccine updates in general?
**Dr. Maria Santos:** I encourage everyone to stay informed and participate in discussions about vaccine updates. Understanding the science behind these changes helps build trust in public health systems. Ultimately, how we respond collectively will determine our resilience against Covid-19 and other future health challenges.
**Interviewer:** Thank you for your insights, Dr. Santos. It’s crucial to consider both scientific and public sentiments as we navigate these updates.
—
**Question for Readers:**
What are your thoughts on the periodic updates of Covid-19 vaccines? Do you believe they are necessary for controlling variants, or do you think it is an overreaction? Share your opinions below, and let’s discuss!
